BACKGROUND: The inability to accurately predict treatment outcomes for cancer patients in terms of tumour response and anticancer drug toxicity is a severe limitation inherent in current approaches to chemotherapy. Many anticancer drugs are metabolically cleared by cytochrome P450 3A4 (CYP3A4), the predominant CYP expressed in liver. CYP3A4 expression exhibits marked interindividual variation and is repressed in acute inflammatory states. OBJECTIVES: (1) To review the relevance of CYP3A4 variability to drug metabolism in the setting of cancer and to understand how inflammation associated with malignancy contributes to both this variability and to adverse treatment outcomes. (2) To examine the relationship between tumour-induced inflammation and repression of CYP3A4 and to explore methods of dosing of anticancer drugs in the setting of advanced cancer. METHODS: Review of relevant literature covering both human and animal studies as well as in vitro mechanistic studies. RESULTS/ CONCLUSIONS: Interindividual variability in CYP3A4 expression is a major confounding factor for effective cancer treatment and methods to predict CYP3A4-mediated drug clearance may have clinical utility in this setting. Although acute inflammation has long been recognised to repress drug metabolism, it is now becoming apparent that cancer patients exhibiting clinical and laboratory features of an inflammatory response have reduced expression of CYP3A4 and possibly other genes relevant to anticancer drug disposition.
BACKGROUND: The inability to accurately predict treatment outcomes for cancerpatients in terms of tumour response and anticancer drug toxicity is a severe limitation inherent in current approaches to chemotherapy. Many anticancer drugs are metabolically cleared by cytochrome P450 3A4 (CYP3A4), the predominant CYP expressed in liver. CYP3A4 expression exhibits marked interindividual variation and is repressed in acute inflammatory states. OBJECTIVES: (1) To review the relevance of CYP3A4 variability to drug metabolism in the setting of cancer and to understand how inflammation associated with malignancy contributes to both this variability and to adverse treatment outcomes. (2) To examine the relationship between tumour-induced inflammation and repression of CYP3A4 and to explore methods of dosing of anticancer drugs in the setting of advanced cancer. METHODS: Review of relevant literature covering both human and animal studies as well as in vitro mechanistic studies. RESULTS/ CONCLUSIONS: Interindividual variability in CYP3A4 expression is a major confounding factor for effective cancer treatment and methods to predict CYP3A4-mediated drug clearance may have clinical utility in this setting. Although acute inflammation has long been recognised to repress drug metabolism, it is now becoming apparent that cancerpatients exhibiting clinical and laboratory features of an inflammatory response have reduced expression of CYP3A4 and possibly other genes relevant to anticancer drug disposition.
Authors: Alexander Liberman; Zhe Wu; Christopher V Barback; Robert Viveros; Sarah L Blair; Lesley G Ellies; David R Vera; Robert F Mattrey; Andrew C Kummel; William C Trogler Journal: ACS Nano Date: 2013-07-01 Impact factor: 15.881
Authors: Johannes J Moes; Frederik E Stuurman; Jeroen J M A Hendrikx; Serena Marchetti; Alwin D R Huitema; Jos H Beijnen; Jan H M Schellens; Bastiaan Nuijen Journal: Drug Deliv Transl Res Date: 2013-06 Impact factor: 4.617
Authors: Marina Kacevska; Andre Mahns; Rohini Sharma; Stephen J Clarke; Graham R Robertson; Christopher Liddle Journal: Pharm Res Date: 2013-04-20 Impact factor: 4.200